4//SEC Filing
Michaelson Jennifer 4
Accession 0000950170-24-056093
CIK 0001789972other
Filed
May 7, 8:00 PM ET
Accepted
May 8, 7:30 PM ET
Size
16.3 KB
Accession
0000950170-24-056093
Insider Transaction Report
Form 4
Michaelson Jennifer
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-05-06$28.54/sh−20,277$578,706→ 129,582 total - Exercise/Conversion
Common Stock
2024-05-06$4.30/sh+50,000$215,000→ 187,582 total - Sale
Common Stock
2024-05-06$27.82/sh−37,723$1,049,454→ 149,859 total - Exercise/Conversion
Common Stock
2024-05-07$4.30/sh+5,606$24,106→ 135,188 total - Sale
Common Stock
2024-05-07$30.06/sh−5,606$168,516→ 129,582 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-06−50,000→ 138,593 totalExercise: $4.30Exp: 2030-10-28→ Common Stock (50,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-07−5,606→ 132,987 totalExercise: $4.30Exp: 2030-10-28→ Common Stock (5,606 underlying)
Footnotes (5)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.35 to $28.34. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.35 to $28.84. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]25% of the shares vested on July 4, 2020, and the remaining shares vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Documents
Issuer
Cullinan Therapeutics, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001838061
Filing Metadata
- Form type
- 4
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 7:30 PM ET
- Size
- 16.3 KB